retatrutide update 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Phase III retatrutide study demonstrates
Description
The trial also demonstrated a favorable tolerability profile for the 7.2mg dose
To qualify, a patient's provider must submit a prior authorization request showing that the patient is being prescribed a GLP-1 for weight loss
Insurance Not covered
rare but serious risks include pancreatitis, gallbladder disease, and kidney problems
Budget smartly : As your dose increases, you could see a rise in monthly costs
